Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 580

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1B
Chunk 580
---
         Sales and marketing   (125,299)  (1,861,456)  (18,884)  (569,896)Research and development   (47,511)  -   (54,982)  - General and administrative   (194,038)  (679,321)  (171,881)  (134,678)Provision for expected credit losses    -   (883,533)  -   (1,314,427)TOTAL OPERATING EXPENSES   (366,848)  (3,424,310)  (245,747)  (2,019,001)                  LOSS FROM OPERATIONS   (235,144)  (194,020)  (221,750)  (227,464)                  FINANCE COSTS   (11,795)  (9,072)  (5,052)  (8,877)                  LOSS BEFORE TAX   (246,939)  (203,092)  (226,802)  (236,341)                  Tax expense                 Deferred tax   -   12,305   12,269   5,090 Income tax   -   (15,799)  (2,613)  (36,272)Total tax (expense)/credit   -   (3,494)  9,656   (31,182)                  NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS   $(246,939) $(206,586) $(217,146) $(267,523)

 41Table of Contents

Revenue. For the year ended December 31, 2024, Chemrex contributed $9,494,577 (99.8%) of total combined revenue of $9,510,646 compared to its contribution of $9,746,587 (99.8%) of total combined revenue of $9,770,806 for the year ended December 31, 2023, a decrease of 2.59% from the prior year. As mentioned above, the revenue decrease in 2024 was due to increased competition in the market, reduced selling price for resin and fiberglass